Skip to main content

Search

Reset all filters
737 Result(s)
Sort by

Investment of 65 million euro in avian vaccines in France

Investment of 65 million euro in avian vaccines in France

Boehringer Ingelheim is set to invest almost €65 million in a high-tech building at its Lyon Portes-des-Alpes site in Saint-Priest, France (Rhône), to meet the growing demand worldwide for avian vaccines
Respiratory Diseases

Respiratory Diseases

We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in respiratory diseases.
Boehringer Ingelheim Access to Healthcare Strategy 2025

Boehringer Ingelheim Access to Healthcare Strategy 2025

Boehringer Ingelheim aspires to be a leader in ensuring improved access by delivering more health to humans, animals and communities around the world. Read more about our holistic approach.
Congress Patient Benefit

Congress Patient Benefit

The participation in scientific congresses is firmly established in the event agenda of any pharmaceutical company. But what is happening behind the doors of congress centers? How do patients benefit from the participation of pharmaceutical represent
vet scholars symposium

vet scholars symposium

Veterinary students and researchers from 38 veterinary schools in North America and Europe gathered at the NIH in August to discuss the future of veterinary medicine.
BI 764532

BI 764532

DLL3/CD3 T-cell engager: DLL3/CD3 T-cell engager
Bees and biodiversity

Bees and biodiversity

At Boehringer Ingelheim we attach great importance to sustainable planting on our company site – and to protecting the bees.
How fast can a cheetah run wild and free?

How fast can a cheetah run wild and free?

Cheetahs’ top speed can reach up to 120km/h. But habitat loss, illegal wildlife trade and hunting made these impressive animals critically endangered.
Biotherapeutics Discovery

Biotherapeutics Discovery

We are applying our deep understanding of disease biology to design a diverse range of novel modalities that are the foundation for life-changing biotherapeutics for patients.
BI Access to Healthcare Strategy_Availability

BI Access to Healthcare Strategy_Availability

Boehringer Ingelheim aspires to be a leader in ensuring improved access by delivering More Health to humans, animals and communities around the world. Read more about our holistic approach, based on partnerships and local empowerment.